Drug treatment in dementia

被引:7
作者
Bullock, R [1 ]
机构
[1] Victoria Hosp, Kingshill Res Ctr, Swindon SN1 4HZ, Wilts, England
关键词
D O I
10.1097/00001504-200107000-00019
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The present review examines the current issues involving the use of drugs in the treatment of the various dementia syndromes, With the introduction of a new cholinesterase inhibitor, galantamine, during 2000, a recap of the symptomatic treatment issues reported during the past year leads on to early attempts at disease modification. Observational reports of the effect of oestrogen and anti-inflammatory drugs have led to therapeutic trials, which have mostly been negative, This may be due to incomplete understanding of mechanism and inappropriate trial design. Statins and vitamin E have been reported as beneficial, and an amyloid vaccine has entered into a clinical trial. The review finishes with some published experience in treating behavioural components of the dementia syndrome, and overall demonstrates how our understanding of the treatment issues continues to unfold. Curr Opin Psychiatry 14:349-353. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:349 / 353
页数:5
相关论文
共 56 条
  • [1] A randomized controlled trial of prednisone in Alzheimer's disease
    Aisen, PS
    Davis, KL
    Berg, JD
    Schafer, K
    Campbell, K
    Thomas, RG
    Weiner, MF
    Farlow, MR
    Sano, M
    Grundman, M
    Thal, LJ
    [J]. NEUROLOGY, 2000, 54 (03) : 588 - 593
  • [2] Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists - The Cache County Study
    Anthony, JC
    Breitner, JCS
    Zandi, PP
    Meyer, MR
    Jurasova, I
    Norton, MC
    Stone, SV
    [J]. NEUROLOGY, 2000, 54 (11) : 2066 - 2071
  • [3] Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study
    Asthana, S
    Craft, S
    Baker, LD
    Raskind, MA
    Birnbaum, RS
    Lofgreen, CP
    Veith, RC
    Plymate, SR
    [J]. PSYCHONEUROENDOCRINOLOGY, 1999, 24 (06) : 657 - 677
  • [4] VITAMIN-E PROTECTS NERVE-CELLS FROM AMYLOID BETA-PROTEIN TOXICITY
    BEHL, C
    DAVIS, J
    COLE, GM
    SCHUBERT, D
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 186 (02) : 944 - 950
  • [5] ARE REACTIVE OXYGEN SPECIES INVOLVED IN ALZHEIMERS-DISEASE
    BENZI, G
    MORETTI, A
    [J]. NEUROBIOLOGY OF AGING, 1995, 16 (04) : 661 - 674
  • [6] Anti-inflammatory drugs protect against Alzheimer disease at low doses
    Broe, GA
    Grayson, DA
    Creasey, HM
    Waite, LM
    Casey, BJ
    Bennett, HP
    Brooks, WS
    Halliday, GM
    [J]. ARCHIVES OF NEUROLOGY, 2000, 57 (11) : 1586 - 1591
  • [7] Effectiveness of rivastigmine in Alzheimer's disease - Participation in trials should be based on clinical uncertainty, not enforcement
    Bullock, R
    Passmore, P
    Wilkinson, D
    Howard, R
    Jones, R
    [J]. BRITISH MEDICAL JOURNAL, 2000, 320 (7233) : 511 - 512
  • [8] Cholinesterase inhibitors: A new class of psychotropic compounds
    Cummings, JL
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (01) : 4 - 15
  • [9] A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
    De Deyn, PP
    Rabheru, K
    Rasmussen, A
    Bocksberger, JP
    Dautzenberg, PLJ
    Eriksson, S
    Lawlor, BA
    [J]. NEUROLOGY, 1999, 53 (05) : 946 - 955
  • [10] Dresser R, 2000, SCIENCE, V289, P869